Harel Insurance Investments & Financial Services Ltd. boosted its position in Biogen Inc (NASDAQ:BIIB) by 77.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 400 shares of the biotechnology company’s stock after purchasing an additional 174 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Biogen were worth $127,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the business. Atlantic Trust LLC purchased a new position in shares of Biogen during the 2nd quarter valued at about $114,000. Horan Capital Advisors LLC. purchased a new position in shares of Biogen during the 3rd quarter valued at about $128,000. Massey Quick Simon & CO. LLC lifted its position in shares of Biogen by 84.8% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 195 shares in the last quarter. Gs Investments Inc. purchased a new position in shares of Biogen during the 2nd quarter valued at about $136,000. Finally, Patten Group Inc. lifted its position in shares of Biogen by 4,308.7% during the 3rd quarter. Patten Group Inc. now owns 20,368 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 19,906 shares in the last quarter. 88.11% of the stock is currently owned by institutional investors and hedge funds.
BIIB has been the topic of a number of analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $390.00 price objective on shares of Biogen in a research report on Monday, December 18th. Nomura lifted their price objective on Biogen from $355.00 to $420.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Royal Bank of Canada reaffirmed a “hold” rating and set a $321.00 price objective on shares of Biogen in a research report on Tuesday, December 5th. SunTrust Banks reaffirmed a “buy” rating and set a $354.00 price objective on shares of Biogen in a research report on Tuesday, October 24th. Finally, Canaccord Genuity initiated coverage on Biogen in a research report on Friday, October 27th. They set a “hold” rating and a $340.00 price objective on the stock. Eight analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $369.03.
Shares of Biogen Inc (BIIB) opened at $343.83 on Monday. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $370.57. The stock has a market capitalization of $72,741.60, a P/E ratio of 28.84, a price-to-earnings-growth ratio of 1.80 and a beta of 0.75.
Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $5.44 by ($0.18). The company had revenue of $3.31 billion for the quarter, compared to the consensus estimate of $3.08 billion. Biogen had a net margin of 20.69% and a return on equity of 38.32%. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.04 EPS. sell-side analysts expect that Biogen Inc will post 24.77 earnings per share for the current year.
In related news, CEO Michel Vounatsos bought 780 shares of the business’s stock in a transaction dated Friday, December 29th. The shares were purchased at an average price of $320.55 per share, with a total value of $250,029.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert W. Pangia sold 5,832 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $329.65, for a total value of $1,922,518.80. Following the transaction, the director now directly owns 23,539 shares in the company, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. In the last three months, insiders have bought 31,560 shares of company stock worth $10,020,858. Corporate insiders own 0.25% of the company’s stock.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.